Talphera (TLPH) Competitors $0.95 +0.01 (+0.93%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$0.98 +0.03 (+2.63%) As of 10/3/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TLPH vs. ABOS, RPTX, PMVP, VTVT, UNCY, OSTX, STRO, QNTM, ELYM, and ABVCShould you be buying Talphera stock or one of its competitors? The main competitors of Talphera include Acumen Pharmaceuticals (ABOS), Repare Therapeutics (RPTX), PMV Pharmaceuticals (PMVP), vTv Therapeutics (VTVT), Unicycive Therapeutics (UNCY), OS Therapies (OSTX), Sutro Biopharma (STRO), Quantum Biopharma (QNTM), Eliem Therapeutics (ELYM), and ABVC BioPharma (ABVC). These companies are all part of the "pharmaceutical products" industry. Talphera vs. Its Competitors Acumen Pharmaceuticals Repare Therapeutics PMV Pharmaceuticals vTv Therapeutics Unicycive Therapeutics OS Therapies Sutro Biopharma Quantum Biopharma Eliem Therapeutics ABVC BioPharma Acumen Pharmaceuticals (NASDAQ:ABOS) and Talphera (NASDAQ:TLPH) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment. Which has higher valuation and earnings, ABOS or TLPH? Talphera has higher revenue and earnings than Acumen Pharmaceuticals. Talphera is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcumen PharmaceuticalsN/AN/A-$102.33M-$2.28-0.76Talphera$650K66.63-$13M-$0.40-2.38 Is ABOS or TLPH more profitable? Acumen Pharmaceuticals' return on equity of -81.39% beat Talphera's return on equity.Company Net Margins Return on Equity Return on Assets Acumen PharmaceuticalsN/A -81.39% -61.96% Talphera N/A -152.38%-64.32% Do insiders & institutionals believe in ABOS or TLPH? 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. Comparatively, 37.7% of Talphera shares are held by institutional investors. 9.3% of Acumen Pharmaceuticals shares are held by company insiders. Comparatively, 5.7% of Talphera shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts recommend ABOS or TLPH? Acumen Pharmaceuticals presently has a consensus target price of $7.00, indicating a potential upside of 304.62%. Talphera has a consensus target price of $5.00, indicating a potential upside of 426.32%. Given Talphera's stronger consensus rating and higher possible upside, analysts clearly believe Talphera is more favorable than Acumen Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acumen Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60Talphera 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00 Does the media favor ABOS or TLPH? In the previous week, Acumen Pharmaceuticals and Acumen Pharmaceuticals both had 2 articles in the media. Acumen Pharmaceuticals' average media sentiment score of 0.78 beat Talphera's score of -0.50 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acumen Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Talphera 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Which has more risk & volatility, ABOS or TLPH? Acumen Pharmaceuticals has a beta of 0.2, meaning that its stock price is 80% less volatile than the S&P 500. Comparatively, Talphera has a beta of 0.03, meaning that its stock price is 97% less volatile than the S&P 500. SummaryAcumen Pharmaceuticals beats Talphera on 8 of the 14 factors compared between the two stocks. Get Talphera News Delivered to You Automatically Sign up to receive the latest news and ratings for TLPH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TLPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLPH vs. The Competition Export to ExcelMetricTalpheraMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.31M$2.63B$6.14B$10.58BDividend YieldN/A56.38%5.67%4.69%P/E Ratio-2.3724.2278.0526.70Price / Sales66.63726.66605.13131.81Price / CashN/A172.1237.9061.31Price / Book2.025.3412.556.55Net Income-$13M$32.92M$3.31B$277.50M7 Day Performance4.81%3.90%4.28%2.42%1 Month Performance72.98%8.79%6.90%8.63%1 Year Performance21.79%-3.79%70.54%31.60% Talphera Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLPHTalphera1.5497 of 5 stars$0.95+0.9%$5.00+426.3%+21.8%$43.31M$650K-2.3719Short Interest ↑Gap DownABOSAcumen Pharmaceuticals3.2219 of 5 stars$1.23-3.9%$7.00+469.1%-27.0%$74.50MN/A-0.5420News CoveragePositive NewsRPTXRepare Therapeutics2.8982 of 5 stars$1.71-0.6%$4.50+163.2%-52.0%$73.46M$53.48M-0.66180News CoveragePositive NewsPMVPPMV Pharmaceuticals2.8966 of 5 stars$1.38+3.0%$5.50+298.6%-5.9%$73.13MN/A-0.8850High Trading VolumeVTVTvTv Therapeutics1.7051 of 5 stars$22.45+1.3%$35.50+58.1%+65.0%$71.62M$1.02M-7.209Gap UpUNCYUnicycive Therapeutics2.3217 of 5 stars$3.98+0.5%$57.00+1,332.2%+23.6%$70.29M$680K-0.979OSTXOS Therapies3.0529 of 5 stars$2.22+0.5%$18.00+710.8%-38.4%$70.25MN/A-2.81N/AAnalyst ForecastSTROSutro Biopharma4.2158 of 5 stars$0.83-6.9%$4.47+439.2%-74.8%$70.22M$62.04M-0.33240Gap DownQNTMQuantum Biopharma0.4999 of 5 stars$18.36-0.7%N/A+301.1%$70.14MN/A-1.31N/ANews CoverageGap UpELYMEliem TherapeuticsN/A$2.31+3.1%N/A-61.2%$68.73MN/A-4.369ABVCABVC BioPharma0.7788 of 5 stars$2.90+1.0%N/A+383.9%$68.27M$510K-17.0630 Related Companies and Tools Related Companies Acumen Pharmaceuticals Alternatives Repare Therapeutics Alternatives PMV Pharmaceuticals Alternatives vTv Therapeutics Alternatives Unicycive Therapeutics Alternatives OS Therapies Alternatives Sutro Biopharma Alternatives Quantum Biopharma Alternatives Eliem Therapeutics Alternatives ABVC BioPharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLPH) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredRIP USA"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fun...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Talphera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Talphera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TLPH Stock Alerts